MedTrace Logo

Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome

NCT04567290 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-07-29

No results posted yet for this study

Summary

The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Chewed ticagrelor

Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets

DRUG

Swallowed ticagrelor

Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets

Sponsors & Collaborators

  • Centro Hospitalario La Concepcion

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2021-08-15
Completion
2021-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567290 on ClinicalTrials.gov